

G B John Mancini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3553817/publications.pdf>

Version: 2024-02-01

75
papers

5,395
citations

147566

31
h-index

85405

71
g-index

76
all docs

76
docs citations

76
times ranked

5852
citing authors

#	ARTICLE	IF	CITATIONS
1	Spontaneous Coronary Artery Dissection. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 645-655.	1.4	591
2	Spontaneous Coronary Artery Dissection. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1148-1158.	1.2	416
3	Contemporary Review on Spontaneous Coronary Artery Dissection. <i>Journal of the American College of Cardiology</i> , 2016, 68, 297-312.	1.2	412
4	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1129-1150.	0.8	367
5	Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2554-2560.	1.2	357
6	Atherosclerotic Plaque Characteristics by ACT Angiography Identify Coronary Lesions That Cause Ischemia. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1-10.	2.3	241
7	Reduction in Cardiovascular Events During Pravastatin Therapy. <i>Circulation</i> , 1995, 92, 2419-2425.	1.6	240
8	Nonatherosclerotic Coronary Artery Disease in Young Women. <i>Canadian Journal of Cardiology</i> , 2014, 30, 814-819.	0.8	230
9	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	1.2	216
10	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 214-233.	0.8	181
11	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1290-1301.	1.2	162
12	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. <i>Canadian Journal of Cardiology</i> , 2011, 27, 635-662.	0.8	160
13	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1553-1568.	0.8	153
14	Angiographic appearance of spontaneous coronary artery dissection with intramural hematoma proven on intracoronary imaging. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, E54-61.	0.7	151
15	Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic Heart Disease. <i>Canadian Journal of Cardiology</i> , 2014, 30, 837-849.	0.8	132
16	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 1124.	3.0	128
17	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1553-1563.	0.8	105
18	Introducing the "Drucebo" effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	2.9	84

#	ARTICLE	IF	CITATIONS
19	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	0.8	62
20	Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. Journal of the American College of Cardiology, 2016, 68, 985-995.	1.2	52
21	Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2020, 75, 2682-2693.	1.2	50
22	Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy. Circulation: Cardiovascular Interventions, 2011, 4, 545-552.	1.4	49
23	Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovascular Research, 2018, 114, 1073-1081.	1.8	49
24	Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology/Canadian Society of Cardiac Surgery Position Statement on Revascularization of Multivessel Coronary Artery Disease. Canadian Journal of Cardiology, 2014, 30, 1482-1491.	0.8	48
25	Spontaneous Coronary Artery Dissection Misdiagnosed as Takotsubo Cardiomyopathy: A Case Series. Canadian Journal of Cardiology, 2015, 31, 1073.e5-1073.e8.	0.8	48
26	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical Chemistry, 2018, 64, 355-362.	1.5	47
27	Development of Cardiovascular Quality Indicators for Rheumatoid Arthritis: Results from an International Expert Panel Using a Novel Online Process. Journal of Rheumatology, 2015, 42, 1548-1555.	1.0	42
28	Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. Journal of the American College of Cardiology, 2018, 72, 2297-2305.	1.2	42
29	Statin Use and Risk for Cataract: A Nested Case-Control Study of 2 Populations in Canada and the United States. Canadian Journal of Cardiology, 2014, 30, 1613-1619.	0.8	40
30	Quantitative Results of Baseline Angiography and Percutaneous Coronary Intervention in the COURAGE Trial. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 320-327.	0.9	37
31	Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery. Heart, 2016, 102, 763-769.	1.2	36
32	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3 (GAUSS-3) Trial. Clinical Cardiology, 2016, 39, 137-144.	0.7	32
33	Changes in left ventricular function after spontaneous coronary artery dissection. Clinical Cardiology, 2017, 40, 149-154.	0.7	32
34	Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. Canadian Journal of Cardiology, 2014, 30, 377-380.	0.8	27
35	Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. Canadian Journal of Cardiology, 2018, 34, 1004-1009.	0.8	24
36	Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. Journal of the American College of Cardiology, 2019, 73, 2049-2058.	1.2	24

#	ARTICLE	IF	CITATIONS
37	Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005079.	0.9	22
38	Validation of an automated method for assessing brachial artery endothelial dysfunction. <i>Canadian Journal of Cardiology</i> , 2002, 18, 259-62.	0.8	21
39	Validation of a new ultrasound method for the measurement of carotid artery intima medial thickness and plaque dimensions. <i>Canadian Journal of Cardiology</i> , 2004, 20, 1355-9.	0.8	20
40	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 286-297.	0.6	20
41	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 2094-2098.	1.6	19
42	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. <i>Atherosclerosis</i> , 2018, 277, 419-424.	0.4	18
43	Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2197-2207.	1.2	18
44	Spontaneous Coronary Artery Dissection (SCAD). <i>Circulation</i> , 2015, 131, e3-5.	1.6	17
45	Angiotensin II type 1 receptor blocker inhibits pulmonary injury. <i>Clinical and Investigative Medicine</i> , 2005, 28, 118-26.	0.3	17
46	Association of skin cholesterol content, measured by a noninvasive method, with markers of inflammation and Framingham risk prediction. <i>American Journal of Cardiology</i> , 2002, 89, 1313-1316.	0.7	16
47	Validation of the Appropriate Use Criteria for Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (from the COURAGE Trial). <i>American Journal of Cardiology</i> , 2015, 116, 167-173.	0.7	15
48	The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia. <i>Clinical Cardiology</i> , 2018, 41, 888-895.	0.7	11
49	Emerging concepts: Angiotensin-converting enzyme inhibition in coronary artery disease. <i>Cardiovascular Drugs and Therapy</i> , 1996, 10, 609-612.	1.3	10
50	Comparison of Cardiovascular Risk Assessment Algorithms to Determine Eligibility for Statin Therapy: Implications for Practice in Canada. <i>Canadian Journal of Cardiology</i> , 2014, 30, 661-666.	0.8	10
51	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1282-1292.	0.8	10
52	CABG for Complex CAD: When Will Evidence-Based Practice Align With Evidence-Based Medicine? <i>Journal of the American College of Cardiology</i> , 2016, 67, 56-58.	1.2	8
53	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1837-1845.	0.8	8
54	Familial Hypercholesterolemia, Familial Combined Hyperlipidemia and Elevated Lipoprotein(a) in Patients with Premature Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1733-1742.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Are Statins out in the COLD? The STATCOPE Trial. Canadian Journal of Cardiology, 2015, 31, 970-973.	0.8	6
56	A Plaque Disruption Index Identifies Patients with Non-STE-Type 1 Myocardial Infarction within 24 Hours of Troponin Positivity. PLoS ONE, 2016, 11, e0164315.	1.1	6
57	Collagenase to facilitate guidewire crossing in chronic total occlusion PCI—The Total Occlusion Study in Coronary Arteries—5 (TOSCA—5) trial. Catheterization and Cardiovascular Interventions, 2022, 99, 1065-1073.	0.7	6
58	Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. Canadian Journal of Cardiology, 2002, 18, 1309-16.	0.8	6
59	Warfarin Monotherapy in Atrial Fibrillation Patients With Stable Coronary Disease One Year After Myocardial Infarction/Stent: Two Birds With One Stone?. Canadian Journal of Cardiology, 2015, 31, 1070-1072.	0.8	5
60	Is It Time to Update How Suspected Angina Is Evaluated prior to the Use of Specialized Tests? Implications Based on a Systematic Review. Cardiology, 2016, 133, 181-190.	0.6	5
61	Redefining the normal angiogram using population-derived ranges for coronary size and shape: validation using intravascular ultrasound and applications in diverse patient cohorts. International Journal of Cardiovascular Imaging, 2007, 23, 441-453.	0.7	4
62	GOAL Canada: Physician Education and Support Can Improve Patient Management. CJC Open, 2020, 2, 49-54.	0.7	4
63	Diagnostic Implications in the Aftermath of the ISCHEMIA Trial. American Journal of Cardiology, 2020, 125, 1438-1440.	0.7	4
64	Association of "hypertriglyceridemic waist" with increased 5-year risk of subclinical atherosclerosis in a multi-ethnic population: a prospective cohort study. BMC Cardiovascular Disorders, 2021, 21, 63.	0.7	4
65	Can We Eliminate Low-Density Lipoprotein Cholesterol-Related Cardiovascular Events Through More Aggressive Primary Prevention Therapy?. Canadian Journal of Cardiology, 2018, 34, 546-551.	0.8	3
66	Effect of Baseline Exercise Capacity on Outcomes in Patients With Stable Coronary Heart Disease (A) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	2
67	Time to Rethink Reducing Cardiovascular Risk: Are We Ready?. Canadian Journal of Diabetes, 2020, 44, 1-3.	0.4	2
68	Response to Letters Regarding Article, "Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy". Circulation, 2008, 118, .	1.6	1
69	Evidence, Guidelines, and Gut Checks: Musings on Entering the Post-Statins Era of Lipid Management. Canadian Journal of Cardiology, 2016, 32, 271-274.	0.8	1
70	New Promises for Refining Risk Stratification From Anatomical and Functional Assessment of Stable Chest Pain. Circulation, 2017, 135, 2333-2335.	1.6	1
71	The Two-Edged Sword of Shared Clinical Decision-Making in the Post-ISCHEMIA World of Stable Coronary Artery Disease Management. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006451.	0.9	1
72	Optimizing the Prevention of Cardiovascular Events. Canadian Journal of Cardiology, 2016, 32, S13-S14.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Myocardial perfusion with single-photon emission computed tomography, multidetector computed tomography, or neither?. Journal of Nuclear Cardiology, 2017, 24, 1722-1724.	1.4	0
74	Does Chronic Obstructive Pulmonary Disease Cause Cardiovascular Disease?. Hypertension, 2018, 71, 409-410.	1.3	0
75	Editorial Commentary: What Determines the Risk of Cardiovascular Disease in Familial Hypercholesterolemia?. Trends in Cardiovascular Medicine, 2021, 31, 216-217.	2.3	0